Abstract Details

Title Real-world Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients with Amyotrophic Lateral Sclerosis

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-012

Objective To determine real-world treatment retention, safety, and tolerability from edaravone-treated patients with amyotrophic lateral sclerosis (ALS) in the MTP-Patient Support® (MTP-PS) program.

Background

Intravenous (IV) edaravone (Radicava®) was authorized by Health Canada in October 2018 for the treatment of ALS and was shown in clinical trials to slow the rate of functional loss associated with ALS. In Canada, the MTP-PS program offers patient support services and is collecting real-world data from edaravone-treated patients with ALS.

Design/Methods This ongoing, observational, real-world study is collecting de-identified data from edaravone-treated patients enrolled in the MTP-PS program for up to 4 years with 4 pre-planned analyses. The Full Analysis Set (FAS) includes edaravone-naïve (Naïve Analysis Set [NAS], patients with no prior edaravone treatment) and edaravone-experienced (Experienced Analysis Set [EAS], patients with prior edaravone treatment) patients. Baseline demographics are assessed at edaravone initiation.

Results This analysis included 616 FAS patients, of which 73% (n=452) were edaravone-naïve. The edaravone-naïve patients were predominantly >55 years old (78%) and male (62%). Most patients had limb-onset ALS (67%) and definite or probable ALS (65%). Most patients (78%) initiated IV edaravone within <6 months of ALS diagnosis and had previous treatment with riluzole (60%). IV edaravone was administered at an infusion clinic for 30% of patients. Patients in the NAS had a mean total ALS Functional Rating Scale-Revised score of 42.1 and a mean forced vital capacity score of 95.8%. Patient retention rate on edaravone was 56.2% and 27.0% for 12 and 24 months, respectively.

Conclusions

This study offers insight into real-world demographics and characteristics of edaravone-treated patients in Canada. Next steps will evaluate treatment retention, safety, and tolerability of edaravone-treated patients. The real-world evidence generated may be valuable for informing clinicians and payers and enhancing patient support services.

Sponsorship: This study was sponsored by MTP-CA

Authors/Disclosures
Dung Pham, PhD PRESENTER	Mr. Pham has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma Canada.
Louise St-Onge	No disclosure on file
Ryan Ng	No disclosure on file
Calum Neish (IQVIA)	No disclosure on file
Belinda Yap (Innomar Strategies)	No disclosure on file
Pinay Kainth	Pinay Kainth has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma Canada. Pinay Kainth has received personal compensation for serving as an employee of Ultragenyx Canada.
Stephen Apple	Stephen Apple has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc.

��ɫ��

��ɫ��